Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis
Journal of Neuro-Oncology, 05/25/2012Horak P et al.
The authors conclude that single–agent imatinib mesylate might be a well–tolerated therapeutic option with high achievement of disease stabilization for preselected patients with recurrent meningiomas. Because of the small cohort, non–randomized design, and highly diverse patient population, they propose future prospective studies to validate the results.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.